H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $51.00 price target on Immunovant (NASDAQ: IMVT).

The analyst commented: "Yesterday, Immunovant announced the full analysis of the Phase 2 proof-of-concept (PoC) study and the development plan of the GD program using IMVT-1402. Recall, the company reported positive initial Phase 2 data in December 2023; yesterday's data further demonstrated batoclimab's positive clinical impact of normalizing T3 and T4 levels in anti-thyroid therapy (ATD) free patients that guided design for the pivotal study that will be carried out for IMVT-1402, the company's next-generation anti-FcRn mAb. We reiterate our Buy rating and price target of $51 for Immunovant."

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $31.44 yesterday.

You May Also Be Interested In